{{cart_num}}
My Cart> Small Molecule Compounds > Inhibitors & Antagonists & Agonists > Metabolic Enzyme & Protease > Ixazomib citrateCAS：1239908-20-3
Molecular Formula：C20H23BCl2N2O9
Molecular Weight：517.12
Storage：Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year
Purity：≥98%
Appearance：White to off-white Solid
Qty：
Size：
| CAS | 1239908-20-3 |
| Name | Ixazomib citrate |
| Molecular Formula | C20H23BCl2N2O9 |
| Molecular Weight | 517.12 |
| Solubility | Soluble in DMSO ≥10mg/mL |
| Purity | ≥98% |
| Appearance | White to off-white Solid |
| Storage | Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year |
| MDL | MFCD29767859 |
| SMILES | B1(OC(=O)C(O1)(CC(=O)O)CC(=O)O)[C@H](CC(C)C)NC(=O)CNC(=O)C2=C(C=CC(=C2)Cl)Cl |
| InChIKey | MBOMYENWWXQSNW-AWEZNQCLSA-N |
| InChI | InChI=1S/C20H23BCl2N2O9/c1-10(2)5-14(21-33-19(32)20(34-21，7-16(27)28)8-17(29)30)25-15(26)9-24-18(31)12-6-11(22)3-4-13(12)23/h3-4，6，10，14H，5，7-9H2，1-2H3，(H，24，31)(H，25，26)(H，27，28)(H，29，30)/t14-/m0/s1 |
| PubChem CID | 56844015 |
| Target Point | Proteasome |
| Passage | Metabolic Enzyme&Protease |
| Background | Ixazomib citrate is a reversible inhibitor of the beta-5 site of chymotrypsin-like proteolytic hydrolysis in the 20S proteasome. |
| Biological Activity | Ixazomib citrate (MLN9708) is a reversible inhibitor of the chymotrypsin-like proteolytic β5 site of the 20S proteasome with an IC50 of 3.4 nM and a Ki of 0.93 nM.[1-3] |
| IC50 | IC50: 3.4 nM (20S proteasome β5)， 31 nM (20S proteasome β1)， 3500 nM (20S proteasome β2)[3] |
| Data Literature Source | [1]. Liu R， et al. A New Perspective for Osteosarcoma Therapy: Proteasome Inhibition by MLN9708/2238 Successfully Induces Apoptosis and Cell Cycle Arrest and Attenuates the Invasion Ability of Osteosarcoma Cells in Vitro. Cell Physiol Biochem. 2017 Jan 27;41(2 [2]. Chauhan D， et al. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res. 2011 Aug 15;17(16):5311-21. [3]. Kupperman E， et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res. 2010 Mar 1;70(5):1970-80. |
| Unit | Bottle |
| Specification | 2mg |
Remark：These protocols are for reference only. Solarbio does not independently validate these methods.
Note：
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.
Sorry, there is no more information.
Manual Download
